A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts
CPT: Pharmacometrics & Systems Pharmacology · 2023-12 · 12 (12) · 2038-2049
DOI: 10.1002/psp4.13052 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 03.10.2023. Verfasst von Jane Knöchel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Disease progression in nonalcoholic steatohepatitis (NASH) is highly heterogenous and remains poorly understood. Fibrosis stage is currently the best predictor for development of end‐stage liver disease and mortality. Better understanding and quantifying the impact of factors affecting NASH and fibrosis is essential to inform a clinical study design. We developed a population Markov model to describe the transition probability between fibrosis stages and mortality using a unique clinical nonalcoholic fatty liver disease cohort with serial biopsies over 3 decades. We evaluated covariate effects on all model parameters and performed clinical trial simulations to predict the fibrosis progression rate for external clinical cohorts. All parameters were estimated with good precision. Age and diagnosis of type 2 diabetes (T2D) were found to be significant predictors in the model. Increase in hepatic steatosis between visits was the most important predictor for progression of fibrosis. Fibrosis progression rate (FPR) was twofold higher for fibrosis stages 0 and 1 (F0‐1) compared to fibrosis stage 2 and 3 (F2‐3). A twofold increase in FPR was observed for T2D. A two‐point steatosis worsening increased the FPR 11‐fold. Predicted fibrosis progression was in good agreement with data from external clinical cohorts. Our fibrosis progression model shows that patient selection, particularly initial fibrosis stage distribution, can significantly impact fibrosis progression and as such the window for assessing drug efficacy in clinical trials. Our work highlights the increase in hepatic steatosis as the most important factor in increasing FPR, emphasizing the importance of well‐defined lifestyle advise for reducing variability in NASH progression during clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
- DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Department of Pharmacy, Uppsala University, Uppsala, Sweden.
- Department of Health, Medicine, and Caring Sciences, Linköping University, Linköping, Sweden.
- Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
ORCID-Profile: Eman Ibrahim, Stergios Kechagias, Mathias Liljeblad, Björn Carlsson, Sebastian Ueckert
Zitieren
APA
Knöchel, J., Bergenholm, L., Ibrahim, E., Kechagias, S., Hansson, S., Liljeblad, M., Nasr, P., Carlsson, B., Ekstedt, M., & Ueckert, S. (2023). A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts. CPT: Pharmacometrics & Systems Pharmacology, 12(12), 2038-2049. https://doi.org/10.1002/psp4.13052
Vancouver
Knöchel J, Bergenholm L, Ibrahim E, Kechagias S, Hansson S, Liljeblad M, et al. A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts. CPT: Pharmacometrics & Systems Pharmacology. 2023;12(12):2038-2049. doi:10.1002/psp4.13052
BibTeX
@article{Knchel2023,
author = {Knöchel, Jane and Bergenholm, Linnéa and Ibrahim, Eman and Kechagias, Stergios and Hansson, Sara and Liljeblad, Mathias and Nasr, Patrik and Carlsson, Björn and Ekstedt, Mattias and Ueckert, Sebastian},
title = {A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2023},
volume = {12},
number = {12},
pages = {2038--2049},
doi = {10.1002/psp4.13052}
}
EUVIMED